A Phase II Study of Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Eribulin (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 02 Jun 2017 Status changed from active, no longer recruiting to discontinued, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.